Researchers Study Pemphigoid Remission Rates

A study of 77 patients highlights the challenges in treating multisite mucous membrane pemphigoid.

Updated on Oct. 28, 2026 in Diseases — General

Bold flat-color editorial illustration of a pipette tip, evoking the precision of medical treatment research. — A retrospective study in JAMA Dermatology of 77 patients found that achieving complete multisite remission for mucous membrane pemphigoid remains difficult. AI Illustration. Upload story photo >

Live Poll

Do you trust site-specific treatment plans more than treatments targeting systemic disease remission?

A retrospective study published in JAMA Dermatology analyzed treatment outcomes for 77 patients suffering from multisite mucous membrane pemphigoid. Researchers found that while all participants saw improvement, achieving complete multisite remission remains a difficult clinical hurdle.

Why it matters

Persistent disease activity in oral and ocular areas frequently prevents patients from reaching full remission, highlighting a critical need for targeted therapies. Identifying these treatment patterns helps clinicians refine care strategies for this chronic condition.

The study found that 45 percent of patients achieved multisite complete remission, with a median time to reach that status of 32.0 months. While 83 percent of participants saw remission at one or more sites, 44 percent of those patients experienced a relapse.

The players

JAMA Dermatology

This is a peer-reviewed medical journal that publishes clinical and research findings in the field of dermatology.

The details

Researchers observed that rituximab-based regimens and Janus kinase inhibitor therapy were associated with higher rates of improvement. However, serious adverse events were noted most frequently in patients treated with cyclophosphamide monotherapy and Janus kinase inhibitors.

October 28, 2026: The study results were published in JAMA Dermatology.

Health Landscape

This study follows a pattern set by the University of Texas Southwestern Medical Center's autoimmune research initiatives regarding chronic condition management. It contributes to the evolving understanding of how systemic therapies can address complex, site-specific mucosal diseases.

Patients with multisite mucous membrane pemphigoid should discuss the potential for relapse with their specialists, as oral and ocular sites remain primary areas of concern. Understanding that remission can take significant time may help individuals manage expectations during long-term treatment.

The takeaway

This research underscores that while medical interventions can provide improvement for pemphigoid patients, complete remission is often a prolonged process requiring careful monitoring. Patients should work closely with their doctors to balance treatment benefits against the risks of serious adverse events.